Loading...
Loading...
PTPI| Name | Value |
|---|---|
| Revenues | 2.5M |
| Cost of Revenue | 0.6M |
| Gross Profit | 2.0M |
| Operating Expense | 3.3M |
| Operating I/L | -1.3M |
| Other Income/Expense | -0.1M |
| Interest Income | 0.1M |
| Pretax | -1.4M |
| Income Tax Expense | 218.0M |
| Net Income/Loss | -219.4M |
Petros Pharmaceuticals, Inc. specializes in men's health therapeutics, primarily focusing on the commercialization and development of Stendra, a prescription medication for erectile dysfunction (ED). Additionally, the company is involved in the development and commercialization of H100, a patented topical formulation for the treatment of acute Peyronie's disease. Petros Pharmaceuticals also markets a line of ED products in the form of vacuum erection device products, catering to the needs of individuals seeking solutions for men's health issues.
